New obesity drug burns fat and preserves muscle - Karolinska study

Muscle loss is the part of GLP-1 therapy that nobody talks about enough. Studies consistently show that 25-40% of the weight lost on semaglutide and tirzepatide comes from lean mass rather than fat - a metabolic trade-off that worries researchers and frustrates patients who want to lose fat, not strength. A new study from Karolinska Institutet, Stockholm University, and several international collaborators, published in the journal Cell in June 2025, reports a completely different approach: a drug that burns fat by activating muscle metabolism rather than suppressing appetite, with no muscle loss in early clinical trials.

TL;DR

Researchers at Karolinska Institutet developed a β2 agonist tablet that activates fat burning through skeletal muscle rather than the gut-brain pathway used by GLP-1 drugs. In Phase I trials involving 73 subjects, the drug lowered blood sugar and increased fat oxidation without reducing muscle mass or causing GLP-1-style gastrointestinal side effects. Phase II is planned. The drug is designed to work alongside GLP-1 medications.

The muscle loss problem on GLP-1 medications

When you take Ozempic, Wegovy, Mounjaro, or Zepbound, the drug works primarily by reducing appetite - you eat less, and your body draws on stored energy. In theory, that stored energy comes from fat. In practice, your body also draws substantially from muscle protein during periods of caloric deficit, particularly if protein intake is low and resistance training is absent.

The clinical trial data is consistent across drugs. The SURMOUNT-1 trial of tirzepatide found that roughly 30% of total weight lost was lean mass. STEP-1 semaglutide data showed similar figures. At higher doses and with faster weight loss, the lean mass loss percentage can be higher still. Researchers describe the threshold at which fat loss and lean mass loss become physiologically balanced as the "Quarter FFM Rule" - and current GLP-1 drugs, used alone without exercise and adequate protein, generally do not meet it.

Why does this matter? Muscle mass determines your resting metabolic rate, your physical capacity, your insulin sensitivity, your bone density, and your long-term independence as you age. Losing substantial lean mass while losing weight does not just affect how you look - it creates real metabolic and functional consequences that persist even if the weight loss itself is successful.

How the new β2 agonist works differently

β2 agonists are a well-known drug class - they are the active compounds in most asthma inhalers. At high doses, they activate metabolism in skeletal muscle, which is where humans burn most of their energy at rest. The challenge has always been that systemic β2 agonism also stimulates the heart, causing dangerous cardiovascular effects at the doses needed to affect metabolism.

The compound developed by Atrogi AB and studied across Karolinska Institutet, Stockholm University, Uppsala University, and international partner institutions was engineered specifically to activate muscle β2 receptors while avoiding cardiac β2 stimulation. The result is a tablet - not an injection - that activates fat burning directly in skeletal muscle without suppressing appetite and without the nausea, vomiting, or constipation that characterise GLP-1 therapy.

Lead researcher Tore Bengtsson of Stockholm University described the implications: "Our results point to a future where we can improve metabolic health without losing muscle mass." Shane C. Wright of Karolinska Institutet added that the drug "represents a completely new type of treatment and has the potential to be of great importance for patients."

What Phase I found

The Phase I clinical trial enrolled 73 subjects - 48 healthy adults and 25 people with type 2 diabetes. The primary aim of Phase I is safety and tolerability, not efficacy measurement, so these numbers are preliminary. That said, the early signal is striking:

• Lower fasting blood sugar levels in participants with type 2 diabetes
• Increased fat oxidation - measured through respiratory exchange ratio and metabolic markers
• Preserved muscle mass across the treatment period
• No significant gastrointestinal side effects
• Acceptable cardiovascular tolerability - the cardiac over-stimulation problem of older β2 agonists was not observed

These results held in both the healthy cohort and the type 2 diabetes group, suggesting the mechanism is robust across metabolic states. Preclinical animal studies had already shown the drug's ability to increase lean mass as a proportion of total body composition - these human Phase I results support translation of that effect.

Designed to work alongside GLP-1 medications

Critically, the researchers designed this compound as a complement to GLP-1 therapy, not a replacement for it. GLP-1 medications are highly effective at reducing appetite and promoting weight loss. Their weak point is the lean mass loss they produce as a side effect of the caloric deficit they create. The β2 agonist addresses exactly that weak point - activating fat metabolism through a different pathway while preserving the muscle that GLP-1 drugs tend to erode.

The two mechanisms do not overlap. GLP-1 agonists work through gut hormone signalling and brain reward pathways. The β2 agonist works through direct skeletal muscle metabolism. Combining them would theoretically deliver the appetite-suppressing, blood-sugar-lowering effects of GLP-1 drugs plus the muscle-sparing fat burning of the β2 agonist - without stacking identical mechanisms or duplicating risks.

Phase II trials by Atrogi AB are now in planning. Given typical drug development timelines, this compound is likely 5-7 years from potential regulatory approval, and even longer from widespread clinical availability. For the vast majority of current GLP-1 users, it is not a near-term option.

What this means for you right now

The research matters because it confirms what exercise physiologists and clinical nutritionists have been saying for years: the lean mass lost during GLP-1 therapy is not inevitable. It is a function of caloric deficit without adequate protein and without resistance exercise to signal that muscle should be maintained. The Karolinska drug demonstrates this mechanistically - the muscle loss is not a required feature of fat loss.

While waiting for combination therapies to reach clinical availability - which will take years - there are two evidence-based interventions that protect lean mass right now:

Protein intake

A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society recommends a minimum of 1.2 grams of protein per kilogram of body weight per day for GLP-1 users. The LEAN-PREP trial currently underway in Kuwait is testing 1.6 g/kg/day. Most GLP-1 users, eating 30-40% less food than before, are not hitting even the 1.2 g/kg threshold without deliberate effort.

Resistance training

Three sessions per week targeting major muscle groups is the threshold above which studies consistently show lean mass preservation during weight loss. Home-based bodyweight exercises - squats, push-ups, rows, lunges, planks - are sufficient. The key is progressive load: the work must be challenging enough to signal to muscle fibres that they are needed.

The micronutrient side of muscle preservation

Protein and exercise are the headline interventions, but micronutrients matter too. Magnesium is required for over 300 enzymatic reactions including muscle protein synthesis. Vitamin D receptors are present in muscle tissue, and deficiency is associated with muscle weakness and higher fall risk. Zinc is a cofactor in the hormonal pathways that regulate muscle protein turnover. All three are among the nutrients most commonly depleted in GLP-1 users eating reduced quantities of food.

GLP-1 Shield is formulated around the specific micronutrient gaps that GLP-1 therapy creates - including the nutrients your muscle needs to survive and maintain itself while you lose weight. Until the next generation of combination therapies is available, closing these gaps is the practical tool you have right now.

Frequently asked questions

What is the new obesity drug from the Karolinska study?

It is a β2 agonist tablet developed by Atrogi AB in collaboration with Karolinska Institutet and Stockholm University. It activates fat burning by stimulating metabolism in skeletal muscle, using a different pathway from GLP-1 drugs. It is currently in Phase I clinical trials - not yet commercially available.

Does it replace GLP-1 medications like Ozempic or Wegovy?

No. The researchers specifically designed it as a complement to GLP-1 therapy, not a replacement. GLP-1 medications suppress appetite effectively; the β2 agonist addresses the lean mass loss problem that GLP-1 drugs create. Phase II trials are planned, but this compound is likely 5-7 years from potential approval.

How much muscle do people lose on GLP-1 medications?

Clinical trial data consistently shows that 25-40% of total weight lost on semaglutide and tirzepatide comes from lean mass rather than fat, particularly in users who do not maintain adequate protein intake and resistance training. This can be reduced substantially with 1.2+ grams of protein per kilogram of body weight daily combined with three resistance sessions per week.

Can I protect my muscle while on Ozempic or Wegovy right now?

Yes. The two most effective strategies are adequate protein intake - a minimum of 1.2 g/kg/day, ideally 1.6 g/kg/day - and resistance exercise three times per week targeting major muscle groups. Micronutrients including magnesium, vitamin D, and zinc also support muscle protein synthesis. These interventions are available now and do not require waiting for new drug approvals.